INTERMITTENT NEGATIVE PRESSURE THERAPY IN THE COMBINED TREATMENT OF PERIPHERAL LYMPHEDEMA.
Identifieur interne : 008272 ( Ncbi/Merge ); précédent : 008271; suivant : 008273INTERMITTENT NEGATIVE PRESSURE THERAPY IN THE COMBINED TREATMENT OF PERIPHERAL LYMPHEDEMA.
Auteurs : C C Campisi ; M. Ryn ; C S Campisi ; P. Di Summa ; F. Boccardo ; C. CampisiSource :
- Lymphology [ 0024-7766 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- therapy : Lymphedema.
- Humans, Negative-Pressure Wound Therapy.
Abstract
Intermittent negative pressure devices were initially developed by NASA to enhance blood perfusion and combat a reduction in orthostatic tolerance. Investigational studies have demonstrated that the pressure differential produces changes in the blood and cardiac systems and also documented changes in weight and cellulite in obese patients. Although the mechanisms are not known, previous investigation has also reported changes in lymphedematous limbs. These initial results suggested to us that the inclusion of intermittent negative pressure into a lymphedema treatment protocol would be beneficial. We subsequently undertook a study of 50 patients with lymphedema adding intermittent negative pressure to our CLyFT protocol and compared them to the CLyFT protocol without intermittent negative pressure. We found a significant difference between the groups with an additional 7% reduction in lymphedema volume (p = 0.008). Our study results indicate that the inclusion of intermittent negative pressure therapy into the CLyFT protocol was beneficial and further incorporation into other protocols should be investigated.
PubMed: 27164765
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000834
- to stream PubMed, to step Curation: 000834
- to stream PubMed, to step Checkpoint: 000834
Links to Exploration step
pubmed:27164765Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">INTERMITTENT NEGATIVE PRESSURE THERAPY IN THE COMBINED TREATMENT OF PERIPHERAL LYMPHEDEMA.</title>
<author><name sortKey="Campisi, C C" sort="Campisi, C C" uniqKey="Campisi C" first="C C" last="Campisi">C C Campisi</name>
</author>
<author><name sortKey="Ryn, M" sort="Ryn, M" uniqKey="Ryn M" first="M" last="Ryn">M. Ryn</name>
</author>
<author><name sortKey="Campisi, C S" sort="Campisi, C S" uniqKey="Campisi C" first="C S" last="Campisi">C S Campisi</name>
</author>
<author><name sortKey="Di Summa, P" sort="Di Summa, P" uniqKey="Di Summa P" first="P" last="Di Summa">P. Di Summa</name>
</author>
<author><name sortKey="Boccardo, F" sort="Boccardo, F" uniqKey="Boccardo F" first="F" last="Boccardo">F. Boccardo</name>
</author>
<author><name sortKey="Campisi, C" sort="Campisi, C" uniqKey="Campisi C" first="C" last="Campisi">C. Campisi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:27164765</idno>
<idno type="pmid">27164765</idno>
<idno type="wicri:Area/PubMed/Corpus">000834</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000834</idno>
<idno type="wicri:Area/PubMed/Curation">000834</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000834</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000834</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000834</idno>
<idno type="wicri:Area/Ncbi/Merge">008272</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">INTERMITTENT NEGATIVE PRESSURE THERAPY IN THE COMBINED TREATMENT OF PERIPHERAL LYMPHEDEMA.</title>
<author><name sortKey="Campisi, C C" sort="Campisi, C C" uniqKey="Campisi C" first="C C" last="Campisi">C C Campisi</name>
</author>
<author><name sortKey="Ryn, M" sort="Ryn, M" uniqKey="Ryn M" first="M" last="Ryn">M. Ryn</name>
</author>
<author><name sortKey="Campisi, C S" sort="Campisi, C S" uniqKey="Campisi C" first="C S" last="Campisi">C S Campisi</name>
</author>
<author><name sortKey="Di Summa, P" sort="Di Summa, P" uniqKey="Di Summa P" first="P" last="Di Summa">P. Di Summa</name>
</author>
<author><name sortKey="Boccardo, F" sort="Boccardo, F" uniqKey="Boccardo F" first="F" last="Boccardo">F. Boccardo</name>
</author>
<author><name sortKey="Campisi, C" sort="Campisi, C" uniqKey="Campisi C" first="C" last="Campisi">C. Campisi</name>
</author>
</analytic>
<series><title level="j">Lymphology</title>
<idno type="ISSN">0024-7766</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term>
<term>Lymphedema (therapy)</term>
<term>Negative-Pressure Wound Therapy</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Humains</term>
<term>Lymphoedème ()</term>
<term>Traitement des plaies par pression négative</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Negative-Pressure Wound Therapy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Lymphoedème</term>
<term>Traitement des plaies par pression négative</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Intermittent negative pressure devices were initially developed by NASA to enhance blood perfusion and combat a reduction in orthostatic tolerance. Investigational studies have demonstrated that the pressure differential produces changes in the blood and cardiac systems and also documented changes in weight and cellulite in obese patients. Although the mechanisms are not known, previous investigation has also reported changes in lymphedematous limbs. These initial results suggested to us that the inclusion of intermittent negative pressure into a lymphedema treatment protocol would be beneficial. We subsequently undertook a study of 50 patients with lymphedema adding intermittent negative pressure to our CLyFT protocol and compared them to the CLyFT protocol without intermittent negative pressure. We found a significant difference between the groups with an additional 7% reduction in lymphedema volume (p = 0.008). Our study results indicate that the inclusion of intermittent negative pressure therapy into the CLyFT protocol was beneficial and further incorporation into other protocols should be investigated.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27164765</PMID>
<DateCreated><Year>2016</Year>
<Month>05</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>06</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>05</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0024-7766</ISSN>
<JournalIssue CitedMedium="Print"><Volume>48</Volume>
<Issue>4</Issue>
<PubDate><Year>2015</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Lymphology</Title>
<ISOAbbreviation>Lymphology</ISOAbbreviation>
</Journal>
<ArticleTitle>INTERMITTENT NEGATIVE PRESSURE THERAPY IN THE COMBINED TREATMENT OF PERIPHERAL LYMPHEDEMA.</ArticleTitle>
<Pagination><MedlinePgn>197-204</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Intermittent negative pressure devices were initially developed by NASA to enhance blood perfusion and combat a reduction in orthostatic tolerance. Investigational studies have demonstrated that the pressure differential produces changes in the blood and cardiac systems and also documented changes in weight and cellulite in obese patients. Although the mechanisms are not known, previous investigation has also reported changes in lymphedematous limbs. These initial results suggested to us that the inclusion of intermittent negative pressure into a lymphedema treatment protocol would be beneficial. We subsequently undertook a study of 50 patients with lymphedema adding intermittent negative pressure to our CLyFT protocol and compared them to the CLyFT protocol without intermittent negative pressure. We found a significant difference between the groups with an additional 7% reduction in lymphedema volume (p = 0.008). Our study results indicate that the inclusion of intermittent negative pressure therapy into the CLyFT protocol was beneficial and further incorporation into other protocols should be investigated.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Campisi</LastName>
<ForeName>C C</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ryn</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Campisi</LastName>
<ForeName>C S</ForeName>
<Initials>CS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Di Summa</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Boccardo</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Campisi</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Lymphology</MedlineTA>
<NlmUniqueID>0155112</NlmUniqueID>
<ISSNLinking>0024-7766</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054843" MajorTopicYN="Y">Negative-Pressure Wound Therapy</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>5</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>5</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27164765</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Boccardo, F" sort="Boccardo, F" uniqKey="Boccardo F" first="F" last="Boccardo">F. Boccardo</name>
<name sortKey="Campisi, C" sort="Campisi, C" uniqKey="Campisi C" first="C" last="Campisi">C. Campisi</name>
<name sortKey="Campisi, C C" sort="Campisi, C C" uniqKey="Campisi C" first="C C" last="Campisi">C C Campisi</name>
<name sortKey="Campisi, C S" sort="Campisi, C S" uniqKey="Campisi C" first="C S" last="Campisi">C S Campisi</name>
<name sortKey="Di Summa, P" sort="Di Summa, P" uniqKey="Di Summa P" first="P" last="Di Summa">P. Di Summa</name>
<name sortKey="Ryn, M" sort="Ryn, M" uniqKey="Ryn M" first="M" last="Ryn">M. Ryn</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008272 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 008272 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:27164765 |texte= INTERMITTENT NEGATIVE PRESSURE THERAPY IN THE COMBINED TREATMENT OF PERIPHERAL LYMPHEDEMA. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27164765" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |